Healios KK (HLOSF)
0.9929
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Healios SG&A Expense (Quarterly): 2.133M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.133M |
September 30, 2023 | 1.848M |
June 30, 2023 | 1.858M |
March 31, 2023 | 2.627M |
December 31, 2022 | 2.582M |
September 30, 2022 | 2.526M |
June 30, 2022 | 2.971M |
March 31, 2022 | 3.021M |
December 31, 2021 | 3.343M |
September 30, 2021 | 3.852M |
Date | Value |
---|---|
June 30, 2021 | 3.161M |
March 31, 2021 | 5.401M |
December 31, 2020 | 3.083M |
September 30, 2020 | 3.185M |
June 30, 2020 | 2.676M |
March 31, 2020 | 2.663M |
December 31, 2019 | 3.816M |
September 30, 2019 | 2.471M |
June 30, 2019 | 1.983M |
March 31, 2019 | 2.334M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.848M
Minimum
Sep 2023
5.401M
Maximum
Mar 2021
2.905M
Average
2.676M
Median
Jun 2020
SG&A Expense (Quarterly) Benchmarks
Takeda Pharmaceutical Co Ltd | 1.812B |
Nxera Pharma Co Ltd | 26.77M |
PeptiDream Inc | 13.94M |
Stemcell Holdings Inc | 0.8358M |
AnGes Inc | 9.706M |